Sarepta Therapeutics has a new drug in the works that could revolutionize treatment for Duchenne muscular dystrophy. This disease, characterized by a progressive weakening of the muscles, has a dismally low survival rate -- many who are afflicted live only into their teens. Results from a 36-week trial have produced promising data showing a meaningful decline in disease progression, and investors are anxiously awaiting 48-week data to be released in coming days.
As a result, the stock has gone on a huge run, with shares more than tripling since early July. This could easily be a $500 million drug in the U.S., and GlaxoSmithKline is close on Sarepta's heels developing a treatment of its own. Sarepta is the one to watch in this space, particularly as the Oct. 9 meeting of the World Muscle Society draws closer. Check out the video below to learn more.
When it comes to a do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is another recent success story in the industry after gaining FDA approval for its innovative obesity drug. However, while the future looks bright, there are still plenty of obstacles ahead for Arena. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for all who sign up. To learn more and get started, click here now.
Brenton Flynn has no positions in the stocks mentioned above. Dave Williamson has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.